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Introduction
Although infrequent, deep sternal wound problems (DSWP) 
such as mediastinitis or a non-fusing sternum following 
sternotomy for cardiac surgery have a significant impact 
on patient recovery. Extended hospital stay and repeated 
surgery is often required, increasing the risk for additional 
complications. Thus, DSWP are associated with an 
increased morbidity and mortality (1,2). It has been shown 
that certain groups of cardiac surgery patients, such as obese 
or diabetic patients, have an increased risk for DSWP (3,4). 
The risk for DSWP can conceivably be reduced by 
preventing infection or boosting tissue healing in the 
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sternal wound. Both might be accomplished by the local 
application of concentrated activated platelets, as in recent 
years it has become apparent that platelets play a pivotal 
role in wound healing processes beyond the well-known 
closing of the endothelial defect. Numerous growth factors 
and chemoattractants are excreted from activated platelets, 
in sufficient amounts to stimulate vascular proliferation and 
attract tissue stem cells (5). In addition platelets also appear 
to have anti-microbial properties (6).
Centrifugal-based platelet concentration methods have 
been developed separating whole blood in a red blood cell 
(RBC) layer, a platelet rich plasma (PRP) layer and a platelet 
poor plasma (PPP) layer. The PRP layer also contains a 
high concentration of leukocytes, which might provide 
additional protection against infection (7). Activation of the 
concentrated platelets brings about the excretion of growth 
factors, and induces the platelet suspension to jellify. This 
PRP gel (PLG) can be applied between the sternal halves, 
immediately prior to closing the sternum, to enhance the 
healing processes.
Methods
Patients 
PLG was applied to all patients receiving elective cardiac 
surgery involving a median sternotomy and cardiopulmonary 
bypass, with a body mass index (BMI) >30 and diagnosed 
diabetes mellitus type 2 (DM 2). The reference group 
constituted of all elective patients with a BMI >30 and DM 
2 receiving on-pump cardiac surgery involving a median 
sternotomy operated upon in the 2-year period before the 
application of PRP. Exclusion criteria for both groups were 
additional treatments possibly affecting DSWP incidence, 
most notably resternotomy and additional antibiotic 
treatment.
This study has been carried out in the Netherlands 
in accordance with the applicable rules concerning the 
review of research ethics committees and informed consent 
(Research Ethics Committee of the Radboud University 
Nijmegen Medical Centre, CMO-registration number 
2018-4304).
PRP preparation and application
Blood (100 mL) was aspirated from the central venous line 
prior to heparin administration and before start of surgery, 
to minimize the activation of the collected platelets. It is 
important not to activate the platelets prior to application, 
as the excretion of growth factors following activation peaks 
within 10 minutes, and is exhausted in 100 minutes (8). 
Blood was anticoagulated with ACD-A (Fresenius Kabi 
NL, The Netherlands) using a ratio of 9 vol. blood to 1 vol. 
ACD-A. The collected blood was centrifuged (Angel whole 
blood separation system, Arthrex, Son en Breugel, The 
Netherlands) and separated in an RBC component, a PRP 
component, and a PPP component. The spin protocol used 
for a volume of 100 mL whole blood: 3,667 rpm 7 min 41 s; 
3,000 rpm 4 min 40 s, yielding PRP with a hematocrit of 
7%, as recommended by the manufacturer.
PRP was diluted with PPP to a final volume of 8–10 mL, 
and stored at room temperature. For PLG patients 1 to 93, 
12 mL of the PPP was used to produce thrombin using the 
Activat device (Arthrex, The Netherlands) according to the 
manufacturer’s protocol, and kept at room temperature. For 
PLG patients 94 to 144, due to production discontinuation, 
the Activat disposable was unavailable. As alternative 
the Clotalyst device (Zimmer Biomet, Dordrecht, The 
Netherlands) was used, which required an additional 11 mL 
whole blood, anticoagulated with 1 mL ACD-A, to produce 
autologous thrombin according to manufacturer’s protocol. 
Clotalyst trombin was kept at 4 ℃ until use. Remaining 
PPP and RBC were returned to the patient during 
cardiopulmonary bypass.
Immedialtely prior to sternal closure, thrombin was 
added to the PRP in a ratio of 1:10. As soon as the activated 
PRP started to jellify (needing 20–60 s), it was administered 
using a blunt large bore needle (Monoject 15 G × 1−1/2" 
blunt cannula, Covidien/Medtronic, Zaltbommel, The 
Netherlands) between the sternal halves which were kept 
approximately 1 mm apart to allow the gel to get stuck 
between, after which the sternal halves were joined. Care 
was taken not to remove any of the activated PRP by cell 
saver suction during closure of the sternotomy wound.
Cardiac surgery
Surgery was performed according to local guidelines. 
Patients were heparinized using an initial dose of 300 IU/kg 
unfractionated heparin (LEO pharma, Breda, The 
Netherlands). During surgery the activated clotting time 
(ACT) was maintained at least 480 s. The antibiotic 
prophylaxis changed during the second year of PLG 
treatment. The reference group and PLG patients 1–60 
were treated with cefuroxim 1,500 mg at least 30 min. 
before incision, which was repeated after 4 hours of surgery 
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or blood loss >2 Liters. PLG patients 60–144 were treated 
with cefazoline (Eurocept, Ankeveen, The Netherlands) 
2,000 mg administered 15−60 min. before incision, which 
was repeated after 4 hours of surgery or more than 500 mL 
administered cell saver blood. Following sternotomy, 
the use of bonewax on the sternum was avoided, as this 
might form an intrasternal barrier and interfere with 
PRP augmented healing. Filtered CO2 flush (2 L/min) 
in the thoracic cavity was administered during valve or 
aortic surgery to prevent the entrapment of intracardial 
air emboli, starting approximately 10–15 minutes prior to 
closing the heart, and stopping after aortic clamp removal. 
Targeted flow rates during cardiopulmonary bypass were 
2.6 L/min/m2, yielding a venous saturation of 70−80%. The 
sternum was closed using 6 to 8 single steel wires or single 
steel wires combined with Zipfix, an implantable cable tie 
system (DePuy Synthes, The Netherlands), at the surgeon’s 
discretion. After surgery protamin hydrochloride was 
administered (in a 1:1 ratio with administered heparin) to 
neutralize residual heparin activity.
Statistics
To compare the perioperative parameters, we used for 
continuous measurements the 2-tailed two-sample t test 
and for binomial values the N-1 two-proportion test. To 
compare DSWP incidence between the reference group 
and the PLG group, the chi square test was applied.
Results
For a four-year period (2014–2017) PLG was applied to 
all (n=166) patients (BMI >30, DM 2) receiving elective 
cardiac surgery involving a median sternotomy and 
cardiopulmonary bypass. Twenty-two patients received a 
resternotomy or an additional surgical intervention which 
could affect the incidence of DSWP, such as the application 
of gentamycin pads, and were excluded. Thus, the PLG 
group consisted of 144 patients. The reference group 
constituted of all (n=129) elective patients (BMI >30, DM 2) 
receiving on-pump cardiac surgery involving a median 
sternotomy operated upon in the 2-year period (2012–2013) 
before the application of PRP. We excluded nine patients 
from this group for receiving a resternotomy and two 
patients who were lost to follow up. Thus, the reference 
group consisted of 118 patients.
To determine whether the reference group and the 
PLG group were equally vulnerable to develop DSWP, we 
compared both groups for several pre- and perioperative 
parameters which might affect the incidence of DSWP 
(3,4,9,10) (Table 1). 
DSWP were considered present when sternal instability 
or dehiscence was reported in the 6-week follow-up report 
or later, or when thorax wound infections requiring surgical 
interventions excluding superficial ones were reported. 
In the reference group 13 out of 118 patients developed 
DSWP, in the PLG treated group 6 out of 144 patients 
developed DSWP (Table 2). In the reference group DSWP 
occurred in 11% of the obese, diabetic patients. Following 
the application of PLG this risk was reduced to 4.2%. 
The PLG group consisted of 144 patients. Twenty-two 
patients were excluded postoperatively from the PLG group 
for various reasons, but were treated with PLG nonetheless. 
PLG was thus applied to 166 patients for a total cost of 
€58,100. Of the 144 patients in the PLG group 6 (4,2%) 
developed DSWP. Without PLG treatment and a risk of 
11%, there would have been approximately 15–16 patients 
with DSWP. This means that the cost of each avoided 
DSWP in this study is €3,875−€3,630.
Discussion
A varying incidence of DSWP following cardiac surgery has 
been reported, ranging from 0.4–3% in unselected patients 
(3,10). In our institution in the years 2011 to 2016 the 
incidence of DSWP in all cardiac surgery patients was 1.3%, 
which corresponds to other reports. Several techniques have 
been shown to reduce the incidence of DSWP, such as the 
application of prophylactic vancomycin (11), or xyphoid-
sparing sternotomy (12). We have focused on the effect of 
sternal PRP application on DSWP incidence. 
Prior to the application of PLG, the characteristics of 
patients who had developed DSWP were examined, to 
establish an optimal target patient population. Hypertension, 
obesity (BMI >30) and DM 2, risk factors for the 
development of DSWP (3,4,9), were determined. The patient 
group with both obesity and DM 2 included 42% of the 
total number of patients with DSWP, while this group was 
only 4.3% of the total patient population. After evaluation 
it was decided to apply PLG to this patient group, to ensure 
feasibility and maximize the potential cost benefit ratio.
With the introduction of an additional treatment 
detrimental side effects can occur, for the sternal application 
of PLG most notably an increase in infections. Therefore, 
postoperative patient temperatures, leukocyte counts and 
C-reactive protein levels were monitored during the first 
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Table 1 Perioperative patient variables
Characteristics Reference group 2012, 2013 PLG group 2014−2017 P
Age [yr] 65.1 [9.2] 64.9 [8.7] 0.86
BMI 33.3 [3.1] 33.5 [2.8] 0.80
Male 65% 74% 0.14
Thr [10
9
/L] 213.4 [62.2] 219.4 [63.4] 0.52
Leukocytes [10
9
/L] 7.8 [1.6] 7.3 [2.4] 0.13
Smoking within last 5 years 19% 25% 0.22
COPD 8% 8% 0.83
Methotrexate use 3% 2% 0.51
Radiation therapy 0% 3% 0.07
Chronic steroid use 2% 0% 0.22
Renal insufficiency 11% 13% 0.59
Previous cardiac surgery 5% 2% 0.08
Dietary treated DM 2 6.7% 2.7% 0.12
Oral DM 2 medication 53.8% 55.5% 0.73
Insulin dependent DM 2 39.5% 41.7% 0.76
CPB [min] 109 [45] 104 [35] 0.37
AoX [min] 65 [26] 65 [26] 0.98
Use of BITA 4% 5% 0.56
Steel wire only closing 75.4% 67.3% 0.15
Average no. of steel wires 7.2 [0.9] 7.3 [0.9] 0.23
Steel wire + tieraps/ethibond 5.9% 23.6% <0.05
Other closing techniques 18.6% 9% <0.05
Comparison of perioperative factors and factors known to affect (sternal) wound healing between the reference group and the platelet 
gel treated group. Numbers between parentheses are SD. PLG, platelet gel; yr, year; BMI, body mass index; Thr, thrombocytes; COPD, 
chronic obstructive pulmonary disease; DM 2, diabetes mellitus type 2; CPB, cardiopulmonary bypass duration; AoX, aortic clamp time 
duration; BITA, bilateral internal thoracic artery.
Table 2 DSWP incidence in PLG group and reference group
Group DSWP No DSWP Total
Reference group 13 105 118
PLG group 6 138 144
Total 19 243 262
Chi-square test incidence DSWP reference group vs. DSWP PLG group, P value is 0.03. DSWP, deep sternal wound problems; PLG, 
platelet leukocyte gel.
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year and 9 months of PLG application (n=67), and compared 
to the reference group. No differences were observed and 
it was concluded no significant additional risk for infection 
was introduced with this technique. In addition, we did not 
want to use substances potentially inducing (auto) immune 
reactions, such as bovine thrombin. Therefore, autologous 
thrombin was used to achieve platelet activation.
The main limitation of this report is the use of a 
retrospective reference group. This was accepted after 
careful deliberation, firstly since we felt PLG to be 
beneficial and did not want to deny it to high risk patients, 
secondly since the low incidence of DSWP would require a 
large patient population to set up a prospective controlled 
study with sufficient power.
To determine possible confounding factors between the 
reference patient group and the PLG patient group, we 
have taken into account the sternal closing techniques, the 
use of BITA grafting and the applied antibiotic prophylaxis. 
There was no difference in BITA use between the reference 
group and the PRP group. Antibiotic regimen was changed 
during this study, following a change in national guidelines, 
from the first generation β-lactam antibiotic ceforuxim to 
the second generation β-lactam antibiotic cefazoline, albeit 
with similar perioperative protocols. The reference group 
and patients 1–60 of the PLG group received ceforuxim, 
patients 61–144 of the PLG group received cefazoline. 
We found no differences in DSWP incidence following 
the change in antibiotic prophylaxis. Another factor which 
might have an effect on the prevalence of DSWP is the 
sternal closure technique. In the reference group sternal 
closure was mostly performed by using single steel wires 
only compared to the PLG group. In the PLG group 
there was increased usage of single steel wires combined 
with Zipfix or ethibond sutures. The rationale being that 
substituting distal steel wiring for Zipfix or ethibond 
improves sternal stability and reduces local pressure by thin 
steel wires. Between both groups there was no significant 
difference in the number of steel wires used per sternum 
when the closing technique was steel wire only. There is 
no apparent correlation between DSWP and the applied 
closing technique in this study, although others found a 
reduction of DSWP when using Zipfix combined with steel 
wiring compared to steel wiring only (11). Of the 13 DSWP 
cases in the reference group, 11 sternums were closed using 
steel wiring only (84%), 2 sternums were closed using steel 
combined with Zipfix or ethibond (16%). Of the 6 patients 
with DSWP in the PLG group 3 sternums were closed 
with steel wiring only (50%), 2 sternums with steel and 
Zipfix or ethibond (33%), and 1 sternum was closed using 
Zipfix only (16%). Tentative P value calculations show no 
significant differences in applied closing techniques between 
the reference group and patients with DSWP from that 
group (P=0.45) and between the PLG treated group and the 
patients with DSWP from that group (P=0.40). However, 
the low number of DSWP likely prevents a possible 
association to reach significance.
Other studies have been performed to evaluate the 
effect of activated PRP on sternal wound infections in 
unselected cardiac surgery patients. Although also with the 
limitation of a retrospective observational design, several 
studies suggest beneficial effects of PLG application on 
deep and superficial sternal wound infections (12-14). In 
contrast, several prospective studies found no effect of 
PLG application in high risk (15) or consecutive cardiac 
patients (16), but as in these studies the control group and 
the study group were smaller compared to our patient 
groups, a significant effect might have been more difficult 
to detect. Another prospective study, with a population size 
comparable to our study, used patient groups with one or 
more risk factors for DSWP (17). In contrast, our patient 
groups exhibited two risk factors, both DM 2 and BMI 
>30, resulting in a patient population with on average a 
higher, and more homogenous risk profile for DSWP, thus 
a decrease in DSWP might have been easier to detect. In 
addition, PRP can be produced and activated via various 
protocols from various manufacturers. Differences in PRP 
preparation methods, potentially concentrating different 
platelet populations, could complicate the comparison of 
results between studies, as it has been reported that different 
platelet types exhibit different activities (18).
A randomized controlled trial would provide proof of the 
effectiveness of PLG in the prevention of DSWP in obese 
DM 2 cardiac patients. There appears, however, at present 
no justifiable reason to approve of such a study in our clinic, 
as the added risk of the PLG treatment appears negligible, 
the overall cost of PLG treatment is far less than the cost 
of even a few DSWP treatments and the results suggest a 
significant decrease in DSWP incidence. The high risk of 
complications and comorbidities of DSWP treatment, with 
extended hospital stay and additional surgical procedures, 
warrants the preventive use of PLG in patients at high risk 
of a disturbed sternal wound healing.
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